

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

COLON DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

Venue: Churchill Ballroom A, Delta Chelsea Hotel, Toronto

Date: Sunday, May 1st, 2011

Time: 09:15 to 10:15 hrs

Dr. Derek Jonker & Dr. Sharlene Gill

- 09:15 WELCOME AND INTRODUCTION DR. D. JONKER / DR. S. GILL
- 9:15 - 10:00 SELECTED APPROVED / OPEN TRIALS FOR DISCUSSION
- CO.21:** A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (CHALLENGE) DR. C. BOOTH
- CRC.6** (CALGB 80702): A PHASE III TRIAL OF 6 VERSUS 12 TREATMENTS OF ADJUVANT FOLFOX PLUS CELECOXIB OR PLACEBO FOR PATIENTS WITH RESECTED STAGE III COLON CANCER DR. F. COUTURE
- CRC.5** (CALGB 80405): A PHASE III TRIAL OF IRINOTECAN/5FU/LEUCOVORIN ~~OR OXALIPLATIN/5FU/LEUCOVORIN~~ WITH BEVACIZUMAB, OR CETUXIMAB, ~~OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB~~ FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM DR. S. BERRY
- CO.20:** A PHASE III RANDOMIZED STUDY OF BRIVANIB ALANINATE (BMS-582664) IN COMBINATION WITH CETUXIMAB (ERBITUX®) VERSUS PLACEBO IN COMBINATION WITH CETUXIMAB (ERBITUX®) IN PATIENTS PREVIOUSLY TREATED WITH COMBINATION CHEMOTHERAPY FOR METASTATIC COLORECTAL CARCINOMA DR. L. SIU
- IND 208:** A PHASE I TRIAL OF PANITUMUMAB + BKM120, AN ORAL PI3K INHIBITOR, IN COLORECTAL CANCER. DR. R. GOODWIN / D. JONKER
- 10:00 – 10:15 INTERGROUP TASK FORCE UPDATE DR. D. JONKER / DR. S. GILL
- NSABP C-11:** A PHASE III STUDY EVALUATING THE ROLE OF PERIOPERATIVE CHEMOTHERAPY AND BEVACIZUMAB IN PATIENTS WITH POTENTIALLY RESECTABLE HEPATIC COLORECTAL METASTASES DR. S. GALLINGER
- 10:15 CLOSING REMARKS